Innovative Immunological and Target Therapies for NMIBC: Recent Clinical Trial Data Shaping the Future : Episode 6
Opinion
Video
Other Emerging Intravesical Therapies in NMIBC
Author(s):
Panelists discuss how both TAR-200 and UGN-102/103 represent innovative approaches to intravesical drug delivery for bladder conditions. TAR-200 uses a novel silicone-based system designed for controlled gemcitabine release, potentially offering extended drug exposure compared with conventional instillations. UGN-102 and UGN-103 employ a proprietary RTGel technology that transforms from liquid to gel form at body temperature, allowing for longer retention of mitomycin (UGN-102) and high-dose botulinum toxin (UGN-103), respectively, in the bladder.
Video Player is loading.
Video content above is prompted by the following:
- What are your thoughts on novel continual intravesical release technologies that are currently in clinical trials?
- TAR-200 (SunRISe trials)
- UGN-102 (ENVISION) and UGN-103 (UTOPIA)
Related Videos
BPH Management: Patient Outcome Evolution
Suzanne B. Merrill, MD, FACS, discusses rBCG and the NMIBC landscape
Final Thoughts and Clinical Trials in NMIBC
Uptake of New Treatments in Urology Practice
Patient Communication and Treatment Adherence in NMIBC
Expert describes implications of neoadjuvant durvalumab approval in MIBC
Sima Porten, MD, on gene-environment interactions in bladder cancer development
Resective Surgery and Minimally Invasive Procedures For BPH
How rBCG EAP could open up access for Anktiva in bladder cancer
Betty Wang, MD, recaps 3 key urologic cancer studies from EAU 2025
Related Content
